ACUR OTC
Acura Pharmaceuticals, Inc.
1W: -1.0%
1M: -0.0%
3M: -88.9%
YTD: -80.0%
1Y: -75.0%
3Y: -99.8%
5Y: -100.0%
$0.00
+0.00 (+0.00%)
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Income Trends
Revenue
$2M
-56.2% ▼
5Y CAGR: -18.9%
Gross Profit
$1M
-58.7% ▼
5Y CAGR: -18.2%
Operating Income
-$1M
-60.2% ▼
Net Income
-$879K
+27.2% ▲
EPS (Diluted)
$-0.02
+58.6% ▲
EBITDA
-$589K
+7.0% ▲
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $3M | $410K | $3M | $4M | $2M |
| YoY Growth | -33.6% | -86.2% | +548.0% | +34.4% | -56.2% |
| Cost of Revenue | $128K | $2K | $2K | $2M | $90K |
| Gross Profit | $3M | $408K | $3M | $4M | $1M |
| Gross Margin | 95.7% | 99.6% | 99.9% | 99.9% | 94.2% |
| R&D Expenses | $4M | $2M | $2M | $2M | $2M |
| SG&A Expenses | $4M | $3M | $2M | $3M | $1M |
| Operating Expenses | $8M | $4M | $3M | $4M | $1M |
| Operating Income | -$5M | -$4M | -$725K | -$758K | -$1M |
| Operating Margin | -176.2% | -954.9% | -27.3% | -21.2% | -77.7% |
| Interest Expense | $596K | $395K | $462K | $450K | $200K |
| Income Before Tax | -$6M | -$4M | -$4M | -$1M | -$879K |
| Tax Expense | -$135K | $0 | $0 | $0 | $0 |
| Net Income | -$6M | -$4M | -$4M | -$1M | -$879K |
| Net Margin | -191.6% | -937.1% | -142.0% | -33.8% | -56.2% |
| EPS (Diluted) | $-0.36 | $-0.18 | $-0.14 | $-0.04 | $-0.02 |
| EBITDA | -$5M | -$3M | -$3M | -$633K | -$589K |
| Shares Outstanding | 16M | 21M | 27M | 32M | 57M |